The abstract is read at the publisher; the summary is JClub's.
Ziftomenib 600 mg plus venetoclax/azacitidine achieved a 46% composite complete remission rate in 48 adults with relapsed/refractory NPM1-mutated acute myeloid leukemia.
- Why it matters: Effective options are needed for adults with relapsed/refractory NPM1-mutated AML, where durable remissions and manageable safety remain challenging.
- What they did: In the KOMET-007 phase 1 trial, adults with R/R NPM1-mutated AML received ziftomenib 200, 400, or 600 mg once daily with standard venetoclax/azacitidine; 600 mg was expanded. Outcomes included CRc and central MRD negativity (<0.01%).
- The result: With ziftomenib 600 mg, 67% (12/18) reached MRD negativity and median duration of response was 8.6 months, while overall survival was not reached; grade ≥3 events included leukopenia (34%) and thrombocytopenia (28%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.